What Fifteen Years of Trauma Research Tells Us and What It Still Can't Answer
The European Journal of Psychotraumatology marked its fifteenth anniversary by asking its editors to survey what the field has learned since 2010. The result is a sweeping map of trauma research: how we define a traumatic event? What trauma does to the mind and body? And which treatments actually hold up?
A few findings stand out. Resilience, not illness, is the most common outcome, roughly two-thirds of people exposed to a potentially traumatic event recover without developing PTSD. For clarity that means if 3 people are exposed 1 will develop PTSD and the other 2 will not. When symptoms do persist, they rarely stay in one lane. Trauma exposure correlates with depression, substance use, prolonged grief, chronic pain, autoimmune disease, obesity and metabolic dysfunction, and cardiovascular events. Notably, PTSD raises cardiovascular risk even after accounting for smoking, diet, and activity level. One reason why for screening broadly and assessing the whole body, not just the psychiatric complaint that brought someone in is critical to that patient’s care.
Sleep deserves particular attention. More than 90% of people with PTSD report insomnia, nightmares, or both, and trauma-focused therapy does not always reliably fix them, over half of patients whose PTSD remits still report insomnia at follow-up. Residual sleep problems predict poorer treatment response and higher relapse risk. Cognitive behavioral therapy for insomnia shows large effects on PTSD symptoms and may support the fear-extinction learning that trauma therapy depends on.
On medication, the review is candid. Sertraline and paroxetine remain the only widely approved options, their effects are modest next to trauma-focused psychotherapy, and current VA/DoD guidance reserves them for when therapy isn't available. A recent meta-analysis of ketamine trials for PTSD concluded that placebo response likely explains the reported benefit, a separate question from esketamine's established role in treatment-resistant depression. MDMA-assisted therapy produced strong phase III results but did not receive FDA approval. Yoga and mindfulness appear as reasonable second-line or adjunctive options, valuable for quality of life rather than as replacements for first-line care.
How much weight should this carry? Appraised with the JBI checklist for text and opinion papers, it performs well: the authors are clearly identified and internationally recognized, the focus stays on the needs of trauma survivors across the lifespan and beyond wealthy Western countries, the reasoning is explicit, and roughly four hundred references anchor it, including places where the evidence conflicts. Two cautions matter. Every author is an editor of the journal, and the citation base leans heavily on that journal's own output. And a narrative review has no search protocol or inclusion criteria, so what was left out is unknowable. Read it as an expert map of the field, not as evidence for any single clinical decision.
The practical takeaway fits root-cause care: assess sleep, metabolic health, and comorbidity alongside trauma symptoms, and lead with the interventions that have the strongest evidence behind them.
Olff M, Hein I, Amstadter AB, et al. The impact of trauma and how to intervene: a narrative review of psychotraumatology over the past 15 years. Eur J Psychotraumatol. 2025;16(1):2458406. doi:10.1080/20008066.2025.2458406
